Gepotidacin (GSK2140944) is a first in class, novel triazaacenaphthylene bacterial type II topoisomerase inhibitor in Phase 3 clinical development for the treatment of gonorrhea and uncomplicated urinary tract infections (acute cystitis). This study tested the equivalency of minimal inhibitory concentrations (MICs) obtained by two reference susceptibility testing methods, agar dilution and broth microdilution, for gepotidacin when tested against various gram-positive and gram-negative organisms. Equivalency, measured as the essential agreement >89.9%, was established between the two methods for determining gepotidacin susceptibility results against Staphylococcus spp., Streptococcus spp. and Escherichia coli. However, for Neisseria gonorrhoeae and Haemophilus influenzae, equivalency was not established, and agar dilution remains the sole dilution reference method for determining gepotidacin MICs against N. gonorrhoeae.

Gepotidacin（GSK2140944）是用于治疗淋病和单纯性尿路感染（急性膀胱炎）的三期临床开发中的一流，新颖的三氮杂ena烯细菌II型拓扑异构酶抑制剂。这项研究测试了针对两种革兰氏阳性和革兰氏阴性生物体测试时，通过两种参考药敏试验方法（琼脂稀释法和肉汤微稀释法）获得的最小抑菌浓度（MICs）对gepotidacin的等效性。在确定吉普达霉素对葡萄球菌属，链球菌属的敏感性结果的两种方法之间建立了等效性，衡量标准为> 89.9％。和大肠杆菌。但是，对于淋病奈瑟菌和流感嗜血杆菌，尚未建立等效性，琼脂稀释仍是确定针对淋病奈瑟菌的gepotidacin MIC的唯一稀释参考方法。